4umt
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
+ | |||
==Structure of MELK in complex with inhibitors== | ==Structure of MELK in complex with inhibitors== | ||
<StructureSection load='4umt' size='340' side='right' caption='[[4umt]], [[Resolution|resolution]] 1.98Å' scene=''> | <StructureSection load='4umt' size='340' side='right' caption='[[4umt]], [[Resolution|resolution]] 1.98Å' scene=''> | ||
Line 5: | Line 6: | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=47W:1-(4-{[3-(ISOQUINOLIN-7-YL)PROP-2-YN-1-YL]OXY}-2-METHOXYBENZYL)PIPERAZINEDIIUM'>47W</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=47W:1-(4-{[3-(ISOQUINOLIN-7-YL)PROP-2-YN-1-YL]OXY}-2-METHOXYBENZYL)PIPERAZINEDIIUM'>47W</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ump|4ump]], [[4umq|4umq]], [[4umr|4umr]], [[4umu|4umu]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ump|4ump]], [[4umq|4umq]], [[4umr|4umr]], [[4umu|4umu]]</td></tr> | ||
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4umt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4umt OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4umt RCSB], [http://www.ebi.ac.uk/pdbsum/4umt PDBsum]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4umt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4umt OCA], [http://pdbe.org/4umt PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4umt RCSB], [http://www.ebi.ac.uk/pdbsum/4umt PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4umt ProSAT]</span></td></tr> |
</table> | </table> | ||
== Disease == | == Disease == | ||
Line 19: | Line 20: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
+ | <div class="pdbe-citations 4umt" style="background-color:#fffaf0;"></div> | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 01:20, 19 January 2017
Structure of MELK in complex with inhibitors
|
Categories: Beke, L | Berdini, V | Bonnet, P | Brehmer, D | Coyle, J E | Day, P J | Frederickson, M | Freyne, E J.E | Gilissen, R A.H J | Hamlett, C C.F | Howard, S | Johnson, C N | Linders, J T.M | McMenamin, R | Meerpoel, L | Patel, S | Rees, D C | Sharff, A | Sommen, F | Wu, T | Fragment based drug design | Transferase